Current Report Filing (8-k)
April 21 2021 - 4:30PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 19, 2021
ZOMEDICA CORP.
|
(Exact name of registrant as specified in its charter)
|
Alberta, Canada
|
|
001-38298
|
|
N/A
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
100 Phoenix Drive, Suite 125, Ann Arbor, Michigan
|
|
48108
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (734) 369-2555
N/A
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☒
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Shares, without par value
|
ZOM
|
NYSE American
|
Item 5.08
|
Shareholder Director Nominations
|
Zomedica Corp. (the “Company”) has scheduled its 2021 annual
meeting of shareholders (the “Meeting”) to be held on July 30, 2021 at 8:30 a.m. (Toronto time) and established June 10, 2021
as the record date for determining shareholders entitled to notice of, and to vote at, the Meeting. Due to concerns regarding the coronavirus
outbreak and to assist in protecting the health and well-being of its shareholders and employees, the Company is holding the Meeting as
a virtual-only meeting, which will be conducted via live audio online webcast.
Because the date of the Meeting will be more than 30 days from the anniversary
of the Company’s 2020 annual meeting of shareholders, the deadline for submission of proposals by shareholders for inclusion in
the Company’s proxy materials in accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), will be the close of business on June 2, 2021, which the Company has determined to be a reasonable time before it expects
to begin to print and distribute its proxy materials prior to the Meeting. Any such proposal must also meet the requirements set forth
in the rules and regulations of the Exchange Act in order to be eligible for inclusion in the proxy materials for the Meeting.
The Business Corporations Act (Alberta) (the “Act”) also permits
shareholders to submit proposals for consideration at an annual meeting. In order to be considered at the Meeting, a proposal under the
Act must be received by the Company by not later than June 28, 2021. A shareholder submitting a proposal must satisfy the requirements
of the Act (including share ownership requirements), and the Company may disregard a proposal in the circumstances described in the Act.
In accordance with the Company’s By-laws, any shareholder who intends
to nominate a person for election as a director must provide notice (“Shareholder Notice”) to the Secretary of the Company
on or before 5 p.m. (Calgary time) on June 30, 2021. Any Shareholder Notice must comply with the specific requirements set forth in the
Company’s By-laws in order to be considered at the Meeting. The Shareholder Notice must be provided to the Secretary by personal
delivery, by email or by facsimile transmission so that it is received in accordance with the By-laws by the deadline stipulated above.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ZOMEDICA CORP.
|
|
|
|
|
|
|
Date: April 21, 2021
|
|
By: /s/ Ann Marie Cotter
|
|
|
Name: Ann Marie Cotter
|
|
|
Title: Chief Financial Officer
|
Zomedica (AMEX:ZOM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zomedica (AMEX:ZOM)
Historical Stock Chart
From Sep 2023 to Sep 2024